Previous 10 | Next 10 |
SHANGHAI, China and CAMBRIDGE, Mass., June 28, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the National Medical Products Administration (NMPA) in China has accepted the New Drug Application (NDA) for repotrectinib for the treatment of adult patients wi...
2023-06-20 10:07:39 ET Gainers: DICE Therapeutics ( DICE ) +38% . iCAD ( ICAD ) +17% . Nuwellis ( NUWE ) +14% . Valneva ( VALN ) +14% . Cano Health ( CANO ) +13% . Losers: Surgalign ( SRGA ) -72% . Gracel...
2023-06-07 11:05:45 ET Shares of Zai Lab (NASDAQ: ZLAB) were down more than 13% Wednesday morning, a day after the biotech company reported phase 3 trials for an oncology therapy it is developing with NovoCure . Zai Lab's stock is down more than 5% so far this year. Zai ...
2023-06-07 10:01:47 ET Gainers: Avrobio ( AVRO ) +10% . Cardiff Oncology ( CRDF ) +8% . IceCure Medical ( ICCM ) +7% . Humacyte ( HUMA ) +6% . TScan Therapeutics ( TCRX ) +4% . Losers: Vaxart ( VXRT ) -27% . Carism...
2023-06-07 08:27:22 ET United Natural Foods ( UNFI ) -24% after Q3 earning release , Mondee Holdings ( MOND ) -24% announces pricing of secondary offering of common stock by selling stockholders. Vaxart ( VXRT ) -23% announces proposed public offe...
2023-06-06 21:51:06 ET Shares of NovoCure Limited ( NASDAQ: NVCR ) reached a 52-week low on Tuesday after the medical device maker and its China-based partner Zai Lab ( ZLAB ) posted late-stage data for their cancer treatment device, Tumor Treating Fields (TTFields), in patients...
2023-06-06 09:02:06 ET NovoCure ( NASDAQ: NVCR ) lost ~10% while Zai Lab Limited ( ZLAB ) shed ~1% in the premarket Tuesday after the companies shared late-stage data for their cancer treatment device, Tumor Treating Fields (TTFields), in patients with lung cancer. A...
Tumor Treating Fields therapy together with standard of care provided a statistically significant and clinically meaningful 3-month improvement in median overall survival versus standard of care with no added systemic toxicities Tumor Treating Fields therapy together with immune checkpo...
Three poster presentations to provide updates on Zai Lab’s oncology programs focused on unresectable solid tumors, ovarian cancer and gastrointestinal stromal tumors Early Phase 1/2 study data from Zai Lab’s internally developed ZL-1211 program support a solid safety/toler...
2023-05-31 10:05:20 ET Gainers: Marker Therapeutics ( MRKR ) +34% . Nano-X Imaging ( NNOX ) +13% . Zai Lab ( ZLAB ) +9% . Invivyd ( IVVD ) +8% . Corbus Pharmaceuticals ( CRBP ) +7% . Losers: Belite Bio ( BLTE ) ...
News, Short Squeeze, Breakout and More Instantly...
First and only NMPA-approved subcutaneous (SC) injectable providing additional flexibility and optionality for gMG patients in China Consistent clinical benefit and safety profile of efgartigimod SC compared to IV demonstrated in Phase 3 ADAPT-SC study Zai Lab Limited (NASDAQ: Z...
Manuscript represents the first publication from China’s gynecology oncology field to be published in Cell Publication highlights first-time learnings about the landscape of ovarian cancer microenvironment stratified by HRD and how a PARP inhibitor perturbs it Data suggest ...
2024-07-05 18:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...